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ABSTRACT
The Japanese encephalitis virus (JEV) is endemic
in many countries in southern Asia and the
western Pacific Rim, with new spread to
previously unrecognized countries. It is an
important cause of childhood neurological
disease associated with permanent
neurological sequelae and death. Fortunately,
JE is a vaccine-preventable disease. The
ChimeriVaxTM-JE (Sanofi Pasteur, Lyon,
France) is a live-attenuated chimeric vaccine
derived from the live-attenuated yellow fever
virus, YF17D, which expresses the envelope
proteins of the attenuated JEV vaccine strain,
SA14-14-2. It is a safe, well-tolerated vaccine
that is highly immunogenic in adults and
children. The average geometric mean
neutralizing antibody titer (GMT) in adults is
1,392 and over 90% of adults remain
seroprotected 5 years after vaccination. In
children and toddlers, more than 80% remain
seroprotected 2 years after primary vaccination
and demonstrate a robust and durable
anamnestic response ([500-fold rise in GMT)
with 99.1% seroprotection rates 1 year after a
booster vaccine dose. The ChimeriVaxTM-JE is
effective in children living in endemic regions
where the vaccine could possibly be integrated
into existing childhood vaccination programs.
ChimeriVaxTM-JE is also indicated for travelers
at risk of JE infection.
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INTRODUCTION
Japanese encephalitis virus (JEV) causes a
serious and potentially life-threatening
infection of the central nervous system of
which children are the most affected.
Although the majority of infections are
asymptomatic, the case fatality is estimated at
20–30% in those who develop clinical disease
and up to 50% of survivors experience life-long
neuropsychiatric sequelae [1, 2]. There is no
specific antiviral treatment for JE infection but
with the availability of safe effective vaccines
that can be integrated into existing childhood
vaccination programs in endemic countries,
there is an opportunity to reduce the adverse
health and economic burden of JEV disease.
Currently, there are three commercial
vaccines licensed for use in several regions of
the world [3–5]. This review will focus on the
live-attenuated JE-chimeric vaccine
[ChimeriVaxTM-JE; also known as IMOJEV and
JE-CV (Sanofi Pasteur, Lyon, France)]. It is a safe
and effective prophylactic vaccine against JE for
adults and children over 12 months of age, and
represents a significant advance from the mouse
brain-derived inactivated JE vaccine that had
been available since 1955. There is emerging
evidence that ChimeriVaxTM-JE is capable of
eliciting long-lasting immunity, even after a
single dose of vaccine, making this vaccine an
attractive option for use in JE endemic regions
of the world.
METHOD
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors. This
review was conducted through a MEDLINE
search, limited to the English language, from
1980 to June 2013 using the following search
terms and filters: Japanese encephalitis, natural
history, virology and vaccine. Manual-search of
reference list of relevant studies, clinical trials
and reviews was also conducted.
Virology of JEV
JEV belongs to the family of Flaviviridae, genus
Flavivirus, and shares antigenic cross-reactivity
with other members of the Flavivirus genus
including dengue virus, Murray Valley
encephalitis virus, Kunjin virus, West Nile
Virus and St Louis encephalitis virus. It is an
enveloped, spherical virus that contains an
11-kb single stranded, positive-sense RNA
genome. The viral genome encodes a single
polyprotein that is cleaved into three structural
proteins (capsid, membrane and envelope) and
seven non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5). The
envelope, E, protein is involved in host
receptor binding and entry, neurovirulence
and tissue tropism, and is the major antigenic
determinant of the host immune response
[6, 7].
There are four major genotypes of JEV based
on the envelope gene, and each genotype has
been shown to have a relatively specific regional
geographic distribution. Genotypes I and III
predominate in the more temperate regions of
Korea, Japan, China, Taiwan, Philippines,
northern Thailand and Cambodia. These
viruses are often associated with epidemics of
JE. In contrast, genotypes II and IV are
associated with endemic infection in southern
Thailand, Malaysia and Indonesia [8]. Genotype
V was identified in association with an epidemic
of encephalitis in Malaysia in 1952 [8] and has
been isolated in the mosquito vector, Culex
tritaeniorhynchus, in China [9].
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Transmission Cycle of JEV and Geographic
Distribution
JEV is transmitted in a zoonotic cycle between
mosquitoes, water birds and pigs. The
principal mosquito vector is the Culex
mosquito, in particular, C tritaeniorhynchus,
an evening- and night-time biting mosquito
[10]. Mosquitoes are zoophilic, feeding on
wading birds (herons and egrets) and pigs,
which are the primary hosts in the infection
cycle. JEV infection causes high-titer viremia
in pigs, which are increasingly recognized as
the most important ecological reservoir for JE
in the amplification and spread of JEV [7].
Humans are incidental end-hosts in the
lifecycle of JEV and not necessary for the
maintenance of the viral transmission due to
low-titer viremia in humans that is
insufficient to infect the biting mosquito
vectors.
JEV is widely distributed throughout Asia
and the Pacific rim, with peak endemicity
centered on equatorial Asia and seasonal
epidemics occurring in the more temperate
regions of southeast Asia, India, Japan, Korea,
Taiwan and mainland China (Fig. 1) [11–14].
In the tropical and subtropical regions of Asia,
transmission of JEV occurs year-round,
peaking during the rainy season, while in
the northern temperate regions, JE follows an
epidemic pattern and is more prevalent during
and after the monsoon rains in summer and
autumn. JE infection in humans has been
tracked according to rainfall patterns,
mosquito numbers and seroconversion in
sentinel animals [15]. More recently, JEV has
been identified in the Torres Strait Islands and
in the Cape York Peninsula of Far North
Queensland in Australia [16–18] and also in
Tibet, formerly believed to be a non-endemic
region [19].
Incidence of JE in Endemic Populations
and Travelers
It has been difficult to accurately determine
the incidence of JE infection because the
majority of infections are subclinical [20].
The extent to which measures to control the
mosquito vector, improvements in
agricultural and commercial animal
husbandry practices and JE vaccination
programs have impacted on the overall
incidence of JE infection has not been
accurately quantified. In 2011, the World
Health Organization (WHO) surveillance data
estimated that the incidence of JE infection
was 1.8 per 100,000 persons, approximately
67,900 new cases annually. However, with
75% of cases occurring in children, the annual
incidence in those aged 0–14 years was 5.4 per
100,000, 3 times higher than the overall
incidence [21].
The expansion of global travel, tourism and
economic opportunities in Asia has seen a large
number of travelers from non-endemic regions
visiting and living in JEV endemic regions, and
this population represents an emerging group at
risk of acquiring JE infection [22–24]. The overall
risk of acquisition of JE in travelers is difficult to
ascertain, as the risk relates directly to activities
that increase the likelihood of mosquito bites,
including season and duration of travel, travel to
rural areas, outdoor activities and
accommodation lacking mosquito screens. A
recent Australian study of short-term travelers
spending \30 days in endemic regions in Asia
during the peak rainy season reported no cases of
JE [25]. In contrast, Hill and co-workers reported
an incidence of 0.2 cases per million travelers
[26] while an earlier study in Swiss and British
travelers reported an incidence of 1.3 cases per
7.1 million travelers [27]. Even though the
incidence is low, travelers from non-endemic
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countries have no pre-existing immunity and are
at risk of acquiring a potentially devastating
neurological infection with permanent sequelae.
The need for vaccination must be weighed up
against the duration of travel and the nature of
activities undertaken.
Clinical Manifestation of JE and Natural
History
Children aged 3–15 years old in endemic areas
are highly susceptible to JE infection. The
incubation period of JE infection ranges from
5 to 15 days following inoculation from an
infected mosquito bite. Symptoms often begin
abruptly with a non-specific febrile illness that
may be self-limiting, or may progress to aseptic
meningitis or encephalitis. Aseptic meningitis
with nausea, vomiting headache, nuchal
rigidity and photophobia is seen in 5–10% of
patients, while encephalitis, the most serious
manifestation of JE, is seen in up to 60–75% of
patients. Encephalitis follows the febrile
prodrome by 2–4 days and is characterized by
altered sensorium, motor and behavioral
abnormalities. Individuals may also manifest
acute flaccid paralysis with areflexia resembling
poliomyelitis, seizures and movement disorders,
typically choreoathetosis, myoclonus and
Parkinsonism [1, 2]. In those with mild non-
neurological disease, clinical improvement
coincides with the onset of defervescence.
However, the motor deficits, movement,
behavioral, psychiatric disorders and learning
deficits often persist and may take several
decades to improve. These long-term sequelae
Fig. 1 Global geographical distribution of Japanese encephalitis. This ﬁgure was obtained from the United States Centers
for disease control and prevention (CDC) Yellow Book [14]
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extend the morbidity of the infection well
beyond the acute period and add to the health
and economic burden to local communities
[28].
Laboratory Diagnosis of JE Infection
Diagnosis of acute JE infection is made by
detecting JEV-specific IgM or a fourfold rise in
JEV-specific IgG in the serum and cerebrospinal
fluid (CSF) by capture enzyme-linked
immunosorbent assay (MAC ELISA). JEV-
specific IgM antibodies rise rapidly and are
detectable in the CSF by day 4 after the onset
of symptoms, and by day 7 in the serum,
followed by a slower rise in JEV-specific IgG
[29, 30]. By day 30 after primary infection, JEV-
specific IgG antibodies are detected in the
serum in 100% of individuals. However, in
endemic regions, JE antibodies may be
confounded by cross-reacting antibodies from
other flavivirus infection such as dengue, tick-
born encephalitis or from previous vaccination
against yellow fever or JE [31, 32]. A fourfold or
greater rise in JE-specific antibodies between
acute and convalescent-phase serum 2–4 weeks
apart is useful in confirming acute infection and
distinguishing from non-JEV flaviviral cross-
reacting antibodies. JEV-specific IgM may also
be detectable in the CSF and has been associated
with a poorer outcome [30]. JEV-specific
neutralizing antibodies can also be determined
by the plaque reduction neutralization test
(PRNT). However, this is a labor-intensive
assay and is usually only available in research
and reference laboratories.
Although conventional nucleic acid
amplification test of CSF and serum are not
used to diagnose acute JE because viremia is
short-lived and of low titer, recent advances in
the real-time RT-PCR technology using loop-
mediated isothermal amplification (RT-LAMP)
could see its use in resource-poor settings [33].
Real-time RT-LAMP is rapid test and easy to
perform using a single tube assay with color
detection visible to the naked eye. It has a
detection limit as low as 0.1 plaque forming
units (pfu). Parida et al. [34] reported a
sensitivity and specificity of RT-LAMP of 100%
and 86%, respectively, and was able to detect
serologically confirmed positive samples missed
by conventional RT-PCR. Its utility and
advantage over the current serological tests
have not yet been determined.
Treatment of JE
There are no specific antiviral treatments for JE,
and any treatments are largely supportive to
control seizures, dystonia, cerebral edema and
respiratory support. Clinical trials of interferon
a-2a, ribavirin and corticosteroids have failed to
show improvement in clinical outcome and are
not recommended [35–37]. Prevention of JE by
vaccination and vector control measures
remains the only enduring options to reduce
the incidence of JE.
JE Preventive Vaccine
Until more recently, the prevention of JE
infection has relied on the use of an
inactivated mouse brain-derived vaccine
developed by BIKEN in Japan since 1955 and
licensed under the name of JE-VAX (BIKEN,
Osaka, Japan). Although it reduced the disease
burden in many JE endemic regions, it was
associated with severe allergic reactions. Three
vaccines have since been developed based on
the neuroattenuated strain of JEV, SA14-14-2.
Two of the vaccines are live-attenuated
vaccines: one developed by Chengdu Institute
of Biological Product, People’s Republic of
China, and the second, the ChimeriVaxTM-JE
Infect Dis Ther (2013) 2:145–158 149
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vaccine developed by Sanofi Pasteur. The third
vaccine (IXIARO; JESPECT in Australia) is an
inactivated Vero cell-derived SA14-14-2 vaccine
developed by Intercell Biomedical (Livingston,
United Kingdom) and distributed by Novartis
Vaccines (Surrey, United Kingdom). Table 1 [3–
5, 38, 39] summarizes the key features of the
inactivated IXIARO and live-attenuated
Chengdu vaccine, while this review will focus
on the ChimeriVaxTM-JE vaccine.
ChimeriVax-JE (JE-CV)
The ChimeriVaxTM-JE vaccine, also known as
IMOJEV and JE-CV, is a live-attenuated
recombinant chimeric virus vaccine based on
the live-attenuated yellow fever virus (YFV)
vaccine, YFV17D, in which genome sequences
encoding the membrane and envelope proteins
of YFV have been replaced with the
corresponding genomes sequences of
the attenuated JEV strain, SA-14-14-2 (Fig. 2).
The ChimeriVaxTM-JE vaccine expresses the
immunogenic envelope protein of JE, but
contains the nucleocapsid protein and
replication machinery of YFV17D. The
ChimeriVax technology was developed by
Chambers et al. [40] at St Louis University
(MO, USA) and further developed into the JE-
chimeric virus at Acambis (Cambridge, UK) [41]
before being licensed by Sanofi Pasteur.
Preclinical Testing
The ChimeriVaxTM-JE vaccine consists of a JEV
clone derived by serial passaging of the SA14-
14-2 strain in serum-free Vero cell culture. The
virus contains a mutation at amino acid 60 of
the M protein that confers a capability to
propagate at high viral titers without loss of
the neuroattenuation phenotype [42]. Full
restoration of neurovirulence to wild-type
Nakayama strain required at least four
reversions in three different E protein
domains, while two simultaneous amino acid
reversions only partially restored
neurovirulence [43]. Small animal model
studies with intracerebral inoculation of
ChimeriVaxTM-JE into mice and non-human
primates (rhesus and cynomolgus monkeys)
have demonstrated that ChimeriVaxTM-JE was
less neurovirulent than the parental YFV17D
[44]. Extensive pre-clinical testing of
ChimeriVaxTM-JE also confirmed the stability
of the attenuated genotype and phenotype, its
robust immunogenicity, the production of low-
level viremia in non-human primates and poor
infectivity in mosquito vectors [45].
Immunogenicity and Durability
of the Immune Response in Adults
One of the first human clinical trials (H-040-
001) examined the tolerability and
immunogenicity of two doses of the
ChimeriVaxTM-JE vaccine compared to the
live-attenuated yellow fever vaccine, YF-VAX
(Sanofi Pasteur, Lyon France), in young health
adults with and without pre-existing YF
immunity [46]. The ChimeriVaxTM-JE vaccine
was well tolerated and all participants,
regardless of prior YF immunity, developed
neutralizing antibodies to the vaccine strain
that cross-neutralized wild-type JEV.
These findings were confirmed in a
subsequent study involving 99 individuals
[47]. In this dose-ranging study, 100% of
individuals who received a dose of 3.8 log10
pfu developed neutralizing antibodies with a
GMT of 201 (95% CI 65–681). Cross-reactive
neutralizing antibodies to the wild-type JE
strains, Nakayama, Beijing-1 and a Vietnamese
902/97 strain were detected in the sera of
vaccine recipients. Previous vaccination with
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YF-VAX did not have a negative effect on the
development of neutralizing antibody
responses to ChimeriVaxTM-JE.
A strong antibody response was observed
after challenging a subset of ChimeriVaxTM-JE
vaccine recipients with a single dose of
inactivated mouse brain-derived JE vaccine
(Nakayama strain; JE-VAX, BIKEN, Osaka,
Japan) [47]. These individuals developed
higher antibody titers against ChimeriVaxTM-
JE than against wild-type strains, demonstrating
that the ChimeriVaxTM-JE vaccine was capable
of eliciting a memory immune response.
The durability and efficacy of the
neutralizing antibody response to the
ChimeriVaxTM-JE vaccine were assessed in a
5-year follow-up study [48]. In this study, 202
young healthy participants from non-endemic
countries received primary vaccination with a
single dose of ChimeriVaxTM-JE vaccine and
were then randomized to receive a booster or no
booster dose at 6 months. At one month after
primary vaccination, 99% of participants
seroconverted and the geometric mean titer
(GMT) of neutralizing antibody obtained by
PNRT that achieved a 50% reduction on in viral
plaques in Vero cell cultures (PRNT50) was 317
(95% CI 260–385). At 6 months, 97% (95% CI
93–99) remained seropositive, with a GMT of
151 (95% CI 125–181). In the group
randomized to receive the booster vaccine at
6 months, 100% were seropositive 1 month
after booster vaccination, with a GMT of 353,
comparable to the post-primary vaccination
level (95% CI 289–432). After 5 years of follow-
up, more than 90% of all participants remained
seropositive, with 95% (95% CI 82–99)
seropositivity in those who received a single-
dose vaccine compared to 97% (95% CI,
85–100) in those who received two doses of
the vaccine. Using the Kaplan–Meier decay
analysis, 87% (95% CI 78–96) of participants
who received a single vaccine and 96% (95% CI
89–100) of participants who received the 2-dose
schedule were predicted to be still seropositive
at 5-year post-vaccination [48].
This study also demonstrated that the
vaccine-induced antibodies were capable of
Fig. 2 Genomic organization of ChimeriVaxTM-JE. Genes
encoding the prM and E proteins of the live-attenuated
yellow fever virus, YF17D, are replaced by the prM and E
genes of the attenuated JEV, SA14-14-2 strain. The
chimeric virus replicates using the YF17D machinery but
expresses the envelope and prM proteins of JEV SA14-14-2
on its external virion. JE Japanese encephalitis, C core
protein gene, preM pre-membrane protein gene, E envelope
protein gene, NS1-NS5 non-structural protein genes 1–5
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neutralizing wild-type JEV. Of the 197
participants, at day 28 post-vaccination, 99.5%
(95% CI 97–100) had neutralizing antibodies
(PRNT50 C10) to at least one strain from a panel
of four wild-type JEV strains consisting of a
genotype I isolate from Korea (1991 TVP-8236),
a genotype II isolate from Thailand (B1034/8), a
genotype III isolate from China (Beijing) and a
genotype IV isolate from Indonesia (JKT
9092/TVP-6265). Up to 95% (95% CI 91–98) of
the participants neutralized at least three of the
four wild-type strains, and 85% (95% CI 80–90)
neutralized all four wild-type strains. Of the 46
participants available at 5-year follow-up, cross-
neutralizing antibodies were still present in 65%
(95% CI 50–79) of single-dose vaccinees
compared to 75% (95% CI 58–88) of those
who received 2 vaccine doses.
In the pivotal Phase III trial of 820
participants, a head-to-head comparison of
ChimeriVaxTM-JE with the inactivated mouse
brain-derived JE vaccine (Nakayama strain), JE-
VAX, showed that the immunogenic response
to a single dose of ChimeriVaxTM-JE was
statistically non-inferior to the 3-dose regimen
of JE-VAX [5]. Seroconversion was recorded in
99.1% (95% CI 98–100) of individuals
vaccinated with ChimeriVaxTM-JE, compared
to 95% (95% CI 92–97) of those who received
JE-VAX. In addition, cross-neutralizing
antibodies to the Nakayama strain were
present in 81% (95% CI 76–85) of the
ChimeriVaxTM-JE group, compared to 75%
(95% CI 70, 80) in the JE-VAX group [5].
In a follow-up study, the durability of
vaccine-induced antibody was estimated by
statistical modeling [49]. Based on the GMT
value at 28-day post-vaccination (GMT 1392 in
the ChimeriVaxTM-JE group), the rate of
antibody decline was gradual enough to confer
seroprotection for up to 10 years post-
vaccination. The median duration of
seroprotection was estimated to exceed
20 years, suggesting that booster vaccination
in adults may be unnecessary. Furthermore,
repeated re-exposure to natural infection in JE
endemic areas may provide sufficient natural
boosting to maintain protective antibody titers
[47, 48].
The Use of ChimeriVaxTM-JE in Children
Since the eradication of polio, JE is now one of
the most important childhood neurological
infections in infants and young children
causing permanent and devastating
neurological sequelae [50]. A number of trials
have now been conducted in children in JE
endemic regions and have reported on the
safety, immunogenicity and seroprotection
rates after ChimeriVaxTM-JE vaccination in the
pediatric population.
In a phase II study of 300 Thai children aged
2–5 years who had previously received a 2-dose
primary vaccination with the mouse brain-
derived inactivated JE vaccine, JE-VAX (JE-
VAX vaccine-primed group), vaccination with
ChimeriVaxTM-JE resulted in seropositivity rates
of 100% (95% CI 96–100) [51]. This compared
with 96% (95% CI 92–98) of 200 vaccination-
naı¨ve toddlers aged 12–24 months who received
their first and only dose of ChimeriVaxTM-JE.
The geometric mean titers, when tested against
the ChimeriVaxTM-JE strain, were 2,634 (95% CI
1,928–3,600) and 281 (95% CI 219–362) in the
JE-VAX vaccine-primed and vaccine naı¨ve
groups, respectively. This suggested firstly,
previous immunization with a non-
ChimeriVaxTM-JE vaccine could elicit a robust
anamnestic response to a different vaccine
strain, and secondly, low antibody titers in the
vaccine naı¨ve toddlers group may be due to an
immature immune system. Cross-neutralizing
antibodies to wild-type JE virus were present in
Infect Dis Ther (2013) 2:145–158 153
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72–81% of the JE-VAX primed group
compared to 3–6% in the vaccine naı¨ve
toddlers. In the JE-VAX vaccine-primed
children, 99% of children had seroprotective
antibody titers against at least 3 of 4 wild-type
JEV, with 89% against 1991-TVP-8236, 89%
against B1034/8, 90% against Beijing, and 91%
against JKT 9092/TVP-6265. In the vaccine
naı¨ve toddlers, 97% demonstrated cross-
neutralization against 1991-TVP-8236, 96%
against B1034/8, 97% against Beijing, and 70%
against JKT 9092/TVP-6265. At 12 months post-
vaccination, the seroprotective rates remained
high in both groups, 84% and 97% in the
2–5 year old children and 12–24 months old
toddlers, respectively, with GMT against the
ChimeriVaxTM-JE strain of 454 and 62 [51].
In a subsequent Phase III study in Thailand
and the Philippines involving 1,200 JE vaccine
naı¨ve children aged 12–18 months, the
seroconversion rate to a single dose of
ChimeriVaxTM-JE was 95% (95% CI 93–96) with
a GMT value of 214 (95% CI 168–271) [38]
against the homologous vaccine strain. In a
follow-up study, the effect of booster
vaccination with ChimeriVaxTM-JE in children
aged 36–42 months who had received the
primary vaccination 2 years prior was reported
[52]. Of the 350 children studied, 80% of primary
vaccinees had seroprotective antibodies at study
commencement, albeit with low GMT values, 39
(95% CI 34–46). Antibody titers increased by
57-fold at 28 days after the booster vaccine with a
GMT value of 2,242 (95% CI 1,913–2,628).
One year post-booster, 99% (95% CI 98–100) of
children remained seroprotected and recorded
GMT values of 596 (95% CI 502–708). In a
subgroup of 14/345 children who failed to
seroconvert after primary vaccination, all
responded to the booster vaccine and recorded
GMT values of 290 (95% CI 118–713). A further
subgroup of children who were seronegative
(PRNT50\1:10) 2 years post-primary
vaccination also demonstrated a robust
response to a booster vaccine. The rapid
anamnestic response to a booster vaccination
reported here would suggest that there is value
in providing a booster vaccine in toddlers who
have received primary vaccination. It remains
uncertain if a similar immune response to
natural infection following primary vaccination
in a toddler from an endemic region may be
sufficient to protect from infection.
Safety of ChimeriVaxTM-JE
and Interactions with Pre-existing
Flavivirus Immunity
There were no reported serious adverse effects
related to the use of ChimeriVaxTM-JE vaccine in
either adults or children from endemic and non-
endemic countries, and in particular, no severe
neurological events, allergic reactions,
anaphylaxis or death. The presence of pre-
existing flavivirus immunity including previous
vaccination with the live-attenuated YF vaccine
did not cause any serious adverse events in
ChimeriVaxTM-JE vaccine recipients [46, 47].
Overall, vaccine-related reactions were
observed in 52.0% (833/1,601, 4,581 events) in
those who received the ChimeriVaxTM-JE
vaccine compared to placebo, 50.6% (204/403,
945 events) [5]. Systemic upset with fever,
irritability and localized injection site
reactions were the commonest adverse
reactions and the reactogenicity of
ChimeriVaxTM-JE was similar to that of a
comparator hepatitis A vaccine, Avaxim 80U
(Sanofi Pasteur, Lyon, France) [51].
Low-level viremia was detected in 5 of 300
children, all of who were asymptomatic [47].
Short-lived low-level asymptomatic viremia was
also seen in some vaccinated adults with a mean
peak viraemia 6.6 pfu/ml, a level not expected
154 Infect Dis Ther (2013) 2:145–158
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to cause adverse environmental impact on
transmission in mosquito vectors.
CONCLUSION
Recent years have seen considerable progress in
the refinement of safe and effective vaccines
against JE. There are three vaccines with good
immunogenicity profile for adults and children,
suitable for those in both JE-endemic and non-
endemic regions, and which can be integrated
into the existing childhood vaccination
programs. The novel recombinant chimeric
live vaccine, ChimeriVaxTM-JE, has been
shown to be highly immunogenic in both
adults and children, with a durable
neutralizing antibody titers and robust
anamnestic response.
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